PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Xiamen Hongxin Electronics Technology Group Inc.
300657
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
VNDA Vanda Pharmaceuticals
- 4.420
- -0.280-5.96%
Close Feb 14 16:00 ET
- 4.400
- -0.020-0.45%
Post 20:01 ET
257.72MMarket Cap-13.39P/E (TTM)
4.590High4.200Low1.98MVolume4.580Open4.700Pre Close8.69MTurnover3.76%Turnover RatioLossP/E (Static)58.31MShares6.75052wk High0.48P/B232.59MFloat Cap3.71052wk Low--Dividend TTM52.62MShs Float33.440Historical High--Div YieldTTM8.30%Amplitude0.450Historical Low4.392Avg Price1Lot Size
Trending Stocks
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
Vanda Pharmaceuticals Stock Forum
Vanda's Earnings Show 17% Growth Despite Losses: Major Pipeline Expansion Could Triple Revenue
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Thursday, 13th February at 4:01 pm
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023
Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023
Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023
Full year 2025 revenue expected to grow to $210 to $250 million
Psychiatry portfolio revenue expected to grow to greate...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY,...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Monday, 3rd February at 7:30 am
• Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis
• Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU
• Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payme...
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Monday, 27th January at 7:00 am
• Highlights faulty FDA review
WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today provides an update on the tradipitant development program.
Gastroparesis is a serious digestive disorder of the stomach. In patients with gastroparesis, food moves too slowly from the...
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals (VNDA) has received FDA Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide-based JAK2 inhibitor designed to treat polycythemia vera (PV). PV is a rare blood cancer affecting approximately 1 in 2000 Americans, characterized by excessive red...
No comment yet